Papers/PMID:42472834
Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.
Critical care (London, England)2026The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
sodium hydrogencarbonate — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Sodium bicarbonate therapy did not significantly reduce 90-day mortality compared to control (58.3% vs. 60.6%; risk ratio [RR], 0.96; 95%CI, 0.86-1.07; p = 0.51).”
Quoted verbatim from Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- intravenous sodium bicarbonate titrated to a pH >= 7.30
- Population
- Adults with severe metabolic acidemia (pH <= 7.20) in the BICAR-ICU and BICAR-ICU2 trials, individual patient data pooled; control arm received no sodium bicarbonate
Effect 0.96 risk ratio, 95% CI 0.86 to 1.07
Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.2026PMID:42472834Permalink